Related Experiment Video

Updated: Jun 7, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development

Dae Won Kim1, Vikram Krishnamurthy, Steven D Bines

  • 1Tumor Immunology Laboratory, Department of General Surgery, Rush University Medical Center, Chicago, IL, USA.

Human Vaccines
|October 27, 2010
PubMed

Insights

The 5T4 cancer vaccine, TroVax, shows promise in treating various cancers by targeting the 5T4 antigen. Clinical trials are exploring its therapeutic potential in patients with advanced tumors.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • The 5T4 oncofetal antigen is overexpressed in many adenocarcinomas, promoting tumor progression and metastasis.
  • Its restricted expression in normal tissues makes 5T4 an attractive target for cancer immunotherapy.

Purpose of the Study:

  • To review the clinical development and therapeutic outcomes of the 5T4-based cancer vaccine, TroVax.
  • To assess the efficacy and safety of TroVax in patients with colorectal, renal cell, and prostate cancers.

Main Methods:

  • Development of a modified vaccinia virus Ankara (MVA) encoding human 5T4 (TroVax).
  • Evaluation of TroVax in murine tumor models and human T cell recognition of 5T4 epitopes.
  • Clinical trials in patients with colorectal, renal cell, and hormone-refractory prostate cancer.

Main Results:

  • TroVax demonstrated therapeutic effects in preclinical tumor models.
  • Human T cells recognized 5T4 epitopes in an HLA-restricted manner, indicating immunogenicity.
  • Clinical trials provided valuable data on TroVax's performance in cancer patients.

Conclusions:

  • The 5T4 antigen is a viable target for cancer vaccine development.
  • TroVax has shown potential as a therapeutic cancer vaccine, warranting further investigation.
  • Lessons learned from clinical trials will guide future development of TroVax and similar immunotherapies.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: